{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:31Z","timestamp":1786207351706,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adoptive cell transfer (ACT) can mediate durable regression in patients with metastatic melanoma, and some patients with initial response may progress, requiring salvage therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report updated follow-up on a retrospective review of patients with metastatic melanoma receiving ACT at a single institution from 2000 to 2022. We identified patients with objective response (RECIST 1.0) or stable disease for at least 6 months (SD6) before experiencing oligoprogression in up to three extracranial sites managed with surgery. The primary outcomes were progression-free survival (PFS) and overall survival (OS) after surgery. We also performed an exploratory analysis for genomic mechanisms of tumor escape.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 138 patients with metastatic melanoma treated with ACT had an objective response or SD6 before experiencing disease progression. Of these, 30 (21%) had extracranial oligoprogression managed with metastasectomy. With a median follow-up of 132\u00a0months (range 5\u2013248), median OS was not reached and median PFS was 10.5\u00a0months. Ten-year OS was 54.7% and plateaued after 6\u00a0years. Four patients with pre- and post-ACT tumor sequencing demonstrated significant mutational evolution, with one patient experiencing loss of two major histocompatibility complex class I-restricted neoantigens recognized by T cells in the original infusion product.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Of patients experiencing oligoprogression after initial response to ACT (complete response, partial response, or SD6), 27% derived durable disease control after surgical management, confirming a potentially viable salvage option for \u201clocal\u201d failures following ACT that may not portend systemic failure. Additional factors related to ACT response and oligoprogression that may guide patient selection for salvage metastasectomy remain undefined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19354-1","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:36:59Z","timestamp":1774114619000},"page":"7935-7943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates"],"prefix":"10.1245","volume":"33","author":[{"given":"Aaron J.","family":"Dinerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle J.","family":"Hitscherich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Schrump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuong D.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared J.","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Li","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1353-539X","authenticated-orcid":false,"given":"Nicholas D.","family":"Klemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"19354_CR1","doi-asserted-by":"publisher","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030. Erratum in: N Engl J Med. 2018;379(22):2185. 10.1056\/NEJMx180040.","DOI":"10.1056\/NEJMoa1504030"},{"key":"19354_CR2","unstructured":"National Comprehensive Cancer Network. (2025). Melanoma (cutaneous, version 2.2025). Retrieved from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf."},{"issue":"19","key":"19354_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med."},{"issue":"19","key":"19354_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa1802357.","journal-title":"N Engl J Med."},{"issue":"13","key":"19354_CR5","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116.","journal-title":"Clin Cancer Res."},{"issue":"20","key":"19354_CR6","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","volume":"34","author":"SL Goff","year":"2016","unstructured":"Goff SL, Dudley ME, Citrin DE, et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol. 2016;34(20):2389\u201397. https:\/\/doi.org\/10.1200\/JCO.2016.66.7220.","journal-title":"J Clin Oncol."},{"issue":"23","key":"19354_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2210233.","journal-title":"N Engl J Med."},{"issue":"1","key":"19354_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s40425-019-0672-3","volume":"7","author":"ND Klemen","year":"2019","unstructured":"Klemen ND, Wang M, Feingold PL, et al. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. J Immunother Cancer. 2019;7(1):196. https:\/\/doi.org\/10.1186\/s40425-019-0672-3.","journal-title":"J Immunother Cancer."},{"issue":"4","key":"19354_CR9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1245\/s10434-019-08099-9","volume":"27","author":"DM Bello","year":"2020","unstructured":"Bello DM, Panageas KS, Hollmann T, et al. Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade. Ann Surg Oncol. 2020;27(4):1180\u20138. https:\/\/doi.org\/10.1245\/s10434-019-08099-9.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"19354_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1245\/s10434-016-5537-0","volume":"24","author":"ND Klemen","year":"2017","unstructured":"Klemen ND, Feingold PL, Goff SL, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann Surg Oncol. 2017;24(1):135\u201341. https:\/\/doi.org\/10.1245\/s10434-016-5537-0.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"19354_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127\u201337. https:\/\/doi.org\/10.1200\/JCO.21.02229.","journal-title":"J Clin Oncol."},{"issue":"14","key":"19354_CR12","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","volume":"28","author":"ST Levi","year":"2022","unstructured":"Levi ST, Copeland AR, Nah S, et al. Neoantigen Identification and response to adoptive cell transfer in anti-PD-1 na\u00efve and experienced patients with metastatic melanoma. Clin Cancer Res. 2022;28(14):3042\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4499.","journal-title":"Clin Cancer Res."},{"issue":"9","key":"19354_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ctrv.2014.06.012","volume":"40","author":"D McDermott","year":"2014","unstructured":"McDermott D, Lebb\u00e9 C, Hodi FS, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40(9):1056\u201364. https:\/\/doi.org\/10.1016\/j.ctrv.2014.06.012.","journal-title":"Cancer Treat Rev."},{"issue":"10","key":"19354_CR14","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346\u201357. https:\/\/doi.org\/10.1200\/JCO.2005.00.240.","journal-title":"J Clin Oncol."},{"issue":"5796","key":"19354_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126\u20139. https:\/\/doi.org\/10.1126\/science.1129003.","journal-title":"Science."},{"issue":"7","key":"19354_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917\u201324. https:\/\/doi.org\/10.1200\/JCO.2010.32.2537.","journal-title":"J Clin Oncol."},{"issue":"11","key":"19354_CR17","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1245\/s10434-021-10489-x","volume":"28","author":"AT Li","year":"2021","unstructured":"Li AT, Vakharia K, Lo SN, et al. Survival outcomes of salvage metastasectomy after failure of modern-era systemic therapy for melanoma. Ann Surg Oncol. 2021;28(11):6109\u201323. https:\/\/doi.org\/10.1245\/s10434-021-10489-x.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"19354_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/CJI.0000000000000333","volume":"43","author":"F Comito","year":"2020","unstructured":"Comito F, Leslie I, Boos L, et al. Oligoprogression after checkpoint inhibition in metastatic melanoma treated with locoregional therapy: a single-center retrospective analysis. J Immunother. 2020;43(8):250\u20135. https:\/\/doi.org\/10.1097\/CJI.0000000000000333.","journal-title":"J Immunother."},{"issue":"10435","key":"19354_CR19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D'Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403(10435):1460\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(24)00319-2.","journal-title":"Lancet."},{"issue":"19","key":"19354_CR20","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","volume":"27","author":"SJ Seitter","year":"2021","unstructured":"Seitter SJ, Sherry RM, Yang JC, et al. Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res. 2021;27(19):5289\u201398. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1171.","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19354-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:48:16Z","timestamp":1786204096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19354"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19354-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sri Krishna has-patents and intellectual property filed by the National Institutes of Health (NIH) pertaining to the use of T cells and T-cell receptors for adoptive cell immunotherapy. Stephanie Goff has received in-kind support (IL-2) for a clinical trial from Iovance.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Ethics"}}]}}